SkyQuest Technology Group has recently published a comprehensive Artificial Intelligence in Genomics Market report, offering a detailed analysis of the product landscape and industry scope while providing insights into the market outlook and future trends from 2025 to 2032. This study segments the market across major regions, each contributing to the growing momentum of market development. The growth of this market is primarily driven by the need to accelerate processes and timelines, reduce drug development and discovery costs, increase partnerships and collaborations among key players, and grow investments in AI in genomics. However, the lack of a skilled AI workforce and ambiguous regulatory guidelines for medical software are expected to restrain market growth during the forecast period.
Artificial Intelligence (AI) in Genomics Market is estimated to be valued at USD 2.6 Bn in 2025 and is expected to reach USD 44.63 Bn in 2032, exhibiting a compound annual growth rate (CAGR) of 50.1% from 2025 to 2032.
The Artificial Intelligence in Genomics Market is witnessing notable growth due to increasing demand across various industries and advancements in technology. Factors such as rising consumer awareness, evolving regulations, and the push for sustainable and innovative solutions are driving market expansion. Additionally, the adoption of Artificial Intelligence in Genomics Market is fueled by its versatile applications and growing focus on efficiency, quality, and performance.
Get a Free Sample PDF of the Report – https://www.skyquestt.com/sample-request/artificial-intelligence-in-genomics-market
Detailed Segmentation and Classification of the report (Market Size and Forecast – 2032, Y-o-Y growth rate, and CAGR):
The Artificial Intelligence in Genomics Market can be segmented based on several factors, including product type, application, end-user, and distribution channel.
Based on technology, the market is segmented into machine learning and other technologies. The machine learning segment dominated this market in 2022, as pharmaceutical companies, CROs, and biotechnology companies have widely adopted machine learning for drug genomics applications. This is because machine learning can extract insights from data sets, accelerating genomic research.
Based on application, the market is segmented into diagnostics, drug discovery & development, precision medicine, agriculture & animal research, and other applications. Diagnostics was the largest application segment in the market, in 2022. The large share of this segment can be attributed to the increasing research on diseases and the decreasing cost of sequencing.
Based on the end user, the market is broadly segmented into pharmaceutical & biotechnology companies; hospitals & healthcare providers; research centers, academic institutes, & government organizations; and other end users. Hospitals & healthcare providers accounted for the second largest share of the market in 2022. Factors such as rising demand for solutions to cut the time and costs of drug development drive the market growth.
Artificial Intelligence in Genomics Market – Regional Analysis:
Based on region, the market has been segmented into North America, Europe, Asia Pacific, and the Rest of the World. In 2022, North America accounted for the largest market share followed by Europe. The large share of North America can be attributed to the increasing research funding and government initiatives for promoting precision medicine in the US.
Top Market Players in Artificial Intelligence in Genomics Market are:
The AI in genomics market is dominated by a few globally established players such as NVIDIA Corporation (US), Microsoft Corporation (US), Google LLC (US), Intel Corporation (US), BenevolentAI (UK), SOPHiA GENETICS (Switzerland), Illumina, Inc. (US), among others.
Artificial Intelligence in Genomics Market Recent Developments and Insights:
In December 2022, Intel Labs and the Perelman School of Medicine at the University of Pennsylvania (Penn Medicine) completed of a joint research study using distributed machine learning (ML) and artificial intelligence (AI) approaches to help international healthcare and research institutions identify malignant brain tumors.
In August 2021, Illumina, Inc. acquired GRAIL to provide patients with access to a potentially life-saving multi-cancer early-detection test.
In March 2021, SOPHiA GENETICS collaborated with Hitachi. This collaboration agreement offered clinical, genomic, and real-world insights to healthcare practitioners and pharmaceutical and biotechnology firms and to further democratize Data-Driven Precision Medicine internationally for the benefit of patients.
You may Also Like
https://issuu.com/skyquest-technology/docs/construction_toys_market_is_shaping_the_innovators
https://issuu.com/skyquest-technology/docs/thermal_mass_flow_meter_market_to_reach_usd_3.81_b
Forward-Looking Insights
The Artificial Intelligence in Genomics Market is set to experience sustained growth, fueled by technological advancements, broader global market access, and rising industry demand. With the industry addressing emerging challenges and capitalizing on new opportunities, it is expected to drive innovation and play a pivotal role in advancing global health and economic progress.
About Company:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact Details:
SkyQuest Technology Group
USA (+1) 351-333-4748
Email: [email protected]
